Intraperitoneal radioimmunotherapy of ovarian cancer with Lu-177-CC49: A phase I/II study

被引:149
作者
Alvarez, RD
Partridge, EE
Khazaeli, MB
Plott, G
Austin, M
Kilgore, L
Russell, CD
Liu, TP
Grizzle, WE
Schlom, J
LoBuglio, AF
Meredith, RF
机构
[1] UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294
[2] UNIV ALABAMA,DEPT NUCL MED,BIRMINGHAM,AL 35294
[3] UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294
[4] UNIV ALABAMA,DEPT RADIAT ONCOL,BIRMINGHAM,AL 35294
[5] NCI,BETHESDA,MD 20892
[6] CANC TREATMENT CTR,TUSCALOOSA,AL
关键词
D O I
10.1006/gyno.1996.4577
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal (LU)-L-177-CC49 antibody. Methods. Patients had disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function, and no previous radiation. Results. The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m(2) (45 mCi/m(2)), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with < 1-cm nodules progressed in less than or equal to 21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at > 6 to 35 months. Conclusions. Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with (LU)-L-177-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study. (C) 1997 Academic Press.
引用
收藏
页码:94 / 101
页数:8
相关论文
共 38 条
  • [1] PERITONEAL CARCINOMATOSIS - IMAGING WITH INTRAPERITONEAL INJECTION OF I-131-LABELED B72.3 MONOCLONAL-ANTIBODY
    CARRASQUILLO, JA
    SUGARBAKER, P
    COLCHER, D
    REYNOLDS, JC
    ESTEBAN, J
    BRYANT, G
    PERENTESIS, P
    YOKOYAMA, K
    ROTMAN, M
    SCHLOM, J
    LARSON, SM
    [J]. RADIOLOGY, 1988, 167 (01) : 35 - 40
  • [2] CHATAL JF, 1989, CANCER RES, V49, P3087
  • [3] COLCHER D, 1987, CANCER RES, V47, P4218
  • [4] COLCHER D, 1988, CANCER RES, V48, P4597
  • [5] DIVGI CR, 1995, J NUCL MED, V36, P586
  • [6] ANTIBODY-GUIDED IRRADIATION OF ADVANCED OVARIAN-CANCER WITH INTRAPERITONEALLY ADMINISTERED RADIOLABELED MONOCLONAL-ANTIBODIES
    EPENETOS, AA
    MUNRO, AJ
    STEWART, S
    RAMPLING, R
    LAMBERT, HE
    MCKENZIE, CG
    SOUTTER, P
    RAHEMTULLA, A
    HOOKER, G
    SIVOLAPENKO, GB
    SNOOK, D
    COURTENAYLUCK, N
    DHOKIA, B
    KRAUSZ, T
    TAYLORPAPADIMITRIOU, J
    DURBIN, H
    BODMER, WF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) : 1890 - 1899
  • [7] STAGE-III OVARIAN-CARCINOMA - AN ANALYSIS OF TREATMENT RESULTS AND COMPLICATIONS FOLLOWING HYPERFRACTIONATED ABDOMINOPELVIC IRRADIATION FOR SALVAGE
    FEIN, DA
    MORGAN, LS
    MARCUS, RB
    MENDENHALL, WM
    SOMBECK, MD
    FREEMAN, DE
    MILLION, RR
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (01): : 169 - 176
  • [8] GALLINGER S, 1993, CANCER RES, V53, P271
  • [9] ADJUVANT THERAPY OF OVARIAN-CANCER WITH RADIOACTIVE MONOCLONAL-ANTIBODY
    HIRD, V
    MARAVEYAS, A
    SNOOK, D
    DHOKIA, B
    SOUTTER, WP
    MEARES, C
    STEWART, JSW
    MASON, P
    LAMBERT, HE
    EPENETOS, AA
    [J]. BRITISH JOURNAL OF CANCER, 1993, 68 (02) : 403 - 406
  • [10] JACOBS AJ, 1993, OBSTET GYNECOL, V82, P586